Literature DB >> 17182689

In vitro treatment of human monocytes/macrophages with myristoylated recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release of beta interferon.

Giorgio Mangino1, Zulema A Percario, Gianna Fiorucci, Gabriele Vaccari, Santiago Manrique, Giovanna Romeo, Maurizio Federico, Matthias Geyer, Elisabetta Affabris.   

Abstract

The viral protein Nef is a virulence factor that plays multiple roles during the early and late phases of human immunodeficiency virus (HIV) replication. Nef regulates the cell surface expression of critical proteins (including down-regulation of CD4 and major histocompatibility complex class I), T-cell receptor signaling, and apoptosis, inducing proapoptotic effects in uninfected bystander cells and antiapoptotic effects in infected cells. It has been proposed that Nef intersects the CD40 ligand signaling pathway in macrophages, leading to modification in the pattern of secreted factors that appear able to recruit and activate T lymphocytes, rendering them susceptible to HIV infection. There is also increasing evidence that in vitro cell treatment with Nef induces signaling effects. Exogenous Nef treatment is able to induce apoptosis in uninfected T cells, maturation in dendritic cells, and suppression of CD40-dependent immunoglobulin class switching in B cells. Previously, we reported that Nef treatment of primary human monocyte-derived macrophages (MDMs) induces a cycloheximide-independent activation of NF-kappaB and the synthesis and secretion of a set of chemokines/cytokines that activate STAT1 and STAT3. Here, we show that Nef treatment is capable of hijacking cellular signaling pathways, inducing a very rapid regulatory response in MDMs that is characterized by the rapid and transient phosphorylation of the alpha and beta subunits of the IkappaB kinase complex and of JNK, ERK1/2, and p38 mitogen-activated protein kinase family members. In addition, we have observed the activation of interferon regulatory factor 3, leading to the synthesis of beta interferon mRNA and protein, which in turn induces STAT2 phosphorylation. All of these effects require Nef myristoylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182689      PMCID: PMC1865981          DOI: 10.1128/JVI.01640-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  105 in total

1.  Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain.

Authors:  C H Lee; K Saksela; U A Mirza; B T Chait; J Kuriyan
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

2.  The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase.

Authors:  S Grzesiek; A Bax; G M Clore; A M Gronenborn; J S Hu; J Kaufman; I Palmer; S J Stahl; P T Wingfield
Journal:  Nat Struct Biol       Date:  1996-04

3.  Cellular distribution of HIV type 1 Nef protein: identification of domains in Nef required for association with membrane and detergent-insoluble cellular matrix.

Authors:  J Kaminchik; R Margalit; S Yaish; H Drummer; B Amit; N Sarver; M Gorecki; A Panet
Journal:  AIDS Res Hum Retroviruses       Date:  1994-08       Impact factor: 2.205

4.  Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.

Authors:  F Kirchhoff; T C Greenough; D B Brettler; J L Sullivan; R C Desrosiers
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

5.  Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells.

Authors:  Y Fujii; K Otake; M Tashiro; A Adachi
Journal:  FEBS Lett       Date:  1996-09-09       Impact factor: 4.124

6.  Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression.

Authors:  M S Künzi; H Farzadegan; J B Margolick; D Vlahov; P M Pitha
Journal:  J Infect Dis       Date:  1995-04       Impact factor: 5.226

7.  Role of STAT2 in the alpha interferon signaling pathway.

Authors:  S Leung; S A Qureshi; I M Kerr; J E Darnell; G R Stark
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

8.  In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture.

Authors:  C Chelucci; H J Hassan; C Locardi; D Bulgarini; E Pelosi; G Mariani; U Testa; M Federico; M Valtieri; C Peschle
Journal:  Blood       Date:  1995-03-01       Impact factor: 22.113

9.  Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients.

Authors:  N J Deacon; A Tsykin; A Solomon; K Smith; M Ludford-Menting; D J Hooker; D A McPhee; A L Greenway; A Ellett; C Chatfield; V A Lawson; S Crowe; A Maerz; S Sonza; J Learmont; J S Sullivan; A Cunningham; D Dwyer; D Dowton; J Mills
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

Review 10.  Multiple effects of interferon on the replication of human immunodeficiency virus type 1.

Authors:  P M Pitha
Journal:  Antiviral Res       Date:  1994-07       Impact factor: 5.970

View more
  34 in total

1.  Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene.

Authors:  Mathieu Goupil; Emilie Bélanger Trudelle; Véronique Dugas; Catherine Racicot-Bergeron; Francine Aumont; Serge Sénéchal; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

2.  Acting locally: innate mucosal immunity in resistance to HIV-1 infection in Kenyan commercial sex workers.

Authors:  X-D Yao; R W Omange; B M Henrick; R T Lester; J Kimani; T B Ball; F A Plummer; K L Rosenthal
Journal:  Mucosal Immunol       Date:  2013-06-26       Impact factor: 7.313

3.  CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection.

Authors:  Rodolfo Silva; Susan Moir; Lela Kardava; Karen Debell; Venkateswara R Simhadri; Sara Ferrando-Martínez; Manuel Leal; José Peña; John E Coligan; Francisco Borrego
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

4.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

Review 5.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

Review 6.  The macrophage in HIV-1 infection: from activation to deactivation?

Authors:  Georges Herbein; Audrey Varin
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

Review 7.  Macrophage signaling in HIV-1 infection.

Authors:  Georges Herbein; Gabriel Gras; Kashif Aziz Khan; Wasim Abbas
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

8.  Nef modulates the immunogenicity of Gag encoded in a non-infectious HIV DNA vaccine.

Authors:  Geraldine Arrode; Ramakrishna Hegde; Yuhuai Jin; Dinesh Kumar Singh; Opendra Narayan; Yahia Chebloune
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

9.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

10.  Inhibition of apoptosis signal-regulating kinase 1 mitigates the pathogenesis of human immunodeficiency virus-associated nephropathy.

Authors:  Anqun Chen; Jin Xu; Han Lai; Vivette D D'Agati; Tian-Jun Guan; Shawn Badal; John Liles; John C He; Kyung Lee
Journal:  Nephrol Dial Transplant       Date:  2021-02-20       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.